How Has the Thyroid Eye Disease TED Market Evolved Historically and What is its Current Size?
The thyroid eye disease ted market has seen considerable growth due to a variety of factors.
• The market for thyroid eye disease (TED) has seen robust growth in the past few years. It is set to expand from $2.15 billion in 2024 to $2.30 billion in 2025 experiencing a compound annual growth rate (CAGR) of 7.0%.
The historical growth can be credited to the surge in thyroid disorders, an intensified focus on patient-centric care, a rise in demand for aesthetic procedures, growing incidences of the disease, and augmented treatment alternatives for TED.
What Is The Projected Growth Of The Thyroid Eye Disease TED Template Market?
The thyroid eye disease ted market is expected to maintain its strong growth trajectory in upcoming years.
• The market for thyroid eye disease (TED) is set to witness significant growth in the near future. The market is predicted to attain a value of $2.97 billion by 2029, expanding at a compound annual growth rate (CAGR) of 6.6%.
The accelerating growth during this period is linked to increasing cases of Graves' disease, heightened funding in various sectors, growth in healthcare spending, escalated use of thyroid hormone replacement therapy, and the growing occurrence of thyroid disease. Key market trends for the forecasted period comprise of technological progression, increasing research and development activities, introduction of innovative drugs, progression in treatment alternatives, and emergence of new surgical procedures.
What Are The Key Drivers Fueling Growth In The Thyroid Eye Disease TED Market?
The growth of the thyroid eye disease (TED) market is anticipated to be fueled by the increasing prevalence of thyroid disorders. Thyroid disorders refer to medical conditions that disrupt the normal functioning of the thyroid gland, which results in hormonal imbalances and leads to conditions including hypothyroidism, hyperthyroidism, goiter, and thyroid eye disease. The increase in thyroid disorders can be attributed to factors such as excessive iodine intake, autoimmune diseases, genetic susceptibility, and greater awareness leading to enhanced diagnostic rates. Thyroid Eye Disease (TED), a common and serious complication of Graves' disease, adds to the surge in thyroid disorder cases, thereby heightening the overall weight and consciousness of thyroid-related conditions. To exemplify, the Canadian Cancer Society, a non-profit, community-based organization in Canada, stated in May 2024 that an estimated 6,600 new cases of thyroid cancer were projected to be diagnosed in Canada in 2024, with approximately 280 expected deaths. Hence, escalating thyroid disorders are the primary driving force behind the expansion of the thyroid eye disease (TED) market.
What Are The Principal Market Segments In The Global Thyroid Eye Disease TED Industry?
The thyroid eye disease (TED) market covered in this report is segmented –
1) By Treatment Type: Medical, Surgical, Combination Of Medical And Surgical
2) By Disease Severity: Mild, Moderate, Severe
3) By Drug Type: Biologics, Small Molecules, Others Drug Type
4) By Route Of Administration: Oral, Intravenous, Subcutaneous
5) By End User: Hospitals, Clinics, Other End Users
Subsegments:
1) By Medical: Corticosteroids, Teprotumumab, Antithyroid Medications, Other Medical Treatments
2) By Surgical: Orbital Decompression Surgery, Eyelid Surgery, Strabismus Surgery
3) By Combination Of Medical and Surgical: Combination of Corticosteroids and Orbital Decompression, Combination of Teprotumumab and Eyelid Surgery, Other Combined Approaches
Pre-Book The Thyroid Eye Disease TED Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are New Trends Impacting The Size Of The Thyroid Eye Disease TED Market?
Leading companies in the thyroid eye disease (TED) market are directing their attention to innovative products, like monoclonal antibody therapies, to create powerful, specific treatments that minimize inflammation, rectify proptosis, and boost overall patient recovery. Monoclonal antibody therapies, made in a laboratory and imitating the immune system's ability to identify and neutralize certain pathogens or unusual cells, are being used as treatments. For example, in September 2024, Amgen Inc., a biotechnology firm from the US, announced the approval of TEPEZZA (teprotumumab) by Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of active thyroid eye disease (TED), a rare but potential vision-damaging autoimmune disorder. This is the first and only treatment specifically approved by the FDA for TED. It offers a specific treatment that helps in decreasing inflammation, swelling, and various other distressing symptoms linked with the disease. This go-ahead is crucial for patients in Japan, as it introduces a new and powerful method to control TED, a rare, progressive condition that creates eye bulging, issues with vision, and eye discomfort.
Who Are the Key Players In The Thyroid Eye Disease TED Market?
Major companies operating in the thyroid eye disease (TED) market are:
• Hoffmann-La Roche AG
• Amgen Inc.
• Genentech Inc.
• Horizon Therapeutics plc
• Pierre Fabre S.A.
• Innovent Biologics Inc.
• ACELYRIN Inc.
• Soleo Health
• Zai Lab Limited
• HanAll Biopharma Co. Ltd.
• Tourmaline Bio Inc.
• Zenas BioPharma Inc.
• Immunovant Inc.
• Verana Health
• Harbour BioMed (Guangzhou) Co. Ltd.
• Sling Therapeutics Inc.
• Crinetics Pharmaceuticals Inc.
• Lassen Therapeutics Inc.
• Viridian Therapeutics Inc.
• Minghui Pharmaceutical Inc.
What Are The Regional Insights Into The Thyroid Eye Disease TED Market?
North America was the largest region in the thyroid eye disease (TED) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the thyroid eye disease (TED) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
